Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Survodutide - Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Survodutide - Boehringer Ingelheim

Alternative Names: BI-456906; BI-456909

Latest Information Update: 26 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim; Zealand Pharma
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis; Obesity
  • Phase II Type 2 diabetes mellitus
  • Phase I Liver cirrhosis

Most Recent Events

  • 26 Dec 2024 Boehringer Ingelheim plans a phase I trial for Obesity in January 2025 (SC) (NCT06745284)
  • 03 Oct 2024 Boehringer Ingelheim initiates enrolment in a phase I trial for Obesity in Belgium (NCT06564441)
  • 02 Oct 2024 Boehringer Ingelheim initiates a phase III LIVERAGE trial in Metabolic dysfunction-associated steatohepatitis (MASH) and Fibrosis in (NCT06632444)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top